{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "Systemic menopausal hormone therapy reduces bothersome hot flushes; this established symptom benefit does not demonstrate dementia or cardiovascular prevention, and testosterone needs its own indication-specific evidence.",
  "implications": "The registered primary-subclaim rule assigns Ζ with High confidence from SC2: systemic menopausal hormone therapy causes vasomotor symptom relief in baseline symptomatic women. Endocrine–thermoregulatory contribution is separately rated Ζ, prevention Β, testosterone for HSDD Ε, and broader testosterone enhancement Γ. Weakest-link would return Β for an unregistered conjunction of these different indications; primary-subclaim and scope-matched return Ζ. The symptom grade does not establish preventive or testosterone efficacy.",
  "limitations": "64 primary reports with 8 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}